Orthobiologics Market Will Reach USD 10.2 Billion By 2025: Grand View Research, Inc.
The global orthobiologics market is expected to reach USD
10.2 billion by 2025, according to a new study by Grand View Research, Inc. The
orthobiologics market is predominantly driven by the increasing orthopedic
disease and musculoskeletal disease burden globally. Moreover, emerging
technological innovations in biomaterials, used in the production of
orthobiologics are presumed to accelerate the market demand over the forecast
period. These predominantly include modifications in graft designs, advent of
recombinant biologic agents, stem cell therapy and cultured tissue scaffolds.
These advancements are
accompanied with the benefits such as enhanced biocompatibility, reduced
surgical time and smaller incisions. Furthermore, these novel solutions are
presumed to efficiently reduce the recurrence of post-operative complications,
which in turn is expected to boost the orthobiologics market during the
forecast period.
Browse full research report on Orthobiologics Market:
http://www.grandviewresearch.com/industry-analysis/orthobiological-products-market
Further Key Findings From
the Study Suggest:
- In 2015, viscosupplementation accounted for the
largest share in the product segment owing to being a cost efficient
therapeutic alternative for symptomatic management of osteoarthritis
- Spinal fusion held the largest share in the
application segment in 2015, owing to presence of third party insurers and
reimbursement structure for fusion enhancement products thus triggering
growth
- In 2015, North America accounted for the dominant
share owing to consistent efforts of industry players in promoting
awareness pertinent to the orthobiological products resulting in
significant rise in adoption rate
- Asia Pacific is anticipated to exhibit an exponential
CAGR as a consequence of significant surge in healthcare spending and
awareness levels with respect to the availability of orthobiologics
- The prominent players are consistently indulging into
extensive strategies to gain competitive position including regional
expansion and mergers & acquisitions to capture a greater market share
- For instance, in November 2015, Bioventus acquired
BioStructures, a bioabsorbable bone graft developer. This acquisition was
carried out to expand orthobiologics product portfolio and grafting
solutions in order to expand their market share
Grand View Research has segmented the orthobiologics market
on the basis of product, application, end use, and region:
Orthobiologics Product Outlook (Revenue, USD Billion,
2014 - 2025)
- Demineralized
Bone Matrix(DBM)
- Allograft
- Bone
Morphogenetic Protein (BMP)
- Viscosupplementation
- Synthetic
Bone Substitutes
- Stem
Cell Therapy
Orthobiologics Application Outlook (Revenue, USD Billion,
2014 - 2025)
- Spinal
Fusion
- Trauma
Repair
- Reconstructive
Surgery
Orthobiologics End-use Outlook (Revenue, USD Billion,
2014 - 2025)
- Hospitals
- Orthopedic
Clinics
Orthobiologics Regional Outlook (Revenue, USD Billion,
2014 - 2025)
- North
America
- U.S
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- Japan
- China
- India
- Latin
America
- Brazil
- Mexico
- Middle
East and Africa
- South
Africa
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
For more information: http://www.grandviewresearch.com
Comments
Post a Comment